drugset / Trial / NCT01299181

A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis

NCT01299181 ↗

Phase 4 Completed 60 enrolled University of Edinburgh NHS Lothian · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators hypothesise that long term statin treatment will improve patients' symptoms through its anti-inflammatory effect. The beneficial effects on patient symptoms (cough, sputum volume, bacterial load, airway function, exercise tolerance, exacerbation frequency and health related quality of life) will be consequent on reduced neutrophilic airways inflammation.

Timeline

Start
2010-11
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 80 mg Oral

Indications